NCT05577845View on ClinicalTrials.gov

5-HT3 Receptor Antagonist (Ramosetron) vs Loperamide for the Treatment of Low Anterior Resection Syndrome(RALARS)

NARecruitingINTERVENTIONAL

Enrollment

212

Participants

Timeline

Start Date

March 27, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2032

Conditions

LARS - Low Anterior Resection Syndrome

Interventions

DRUG

Ramosetron

Ramosetron, 4 weeks

Trial Locations (1)

03080

RECRUITING

Seoul National University Hospital, Seoul

All Listed Sponsors

lead

Seoul National University Hospital

OTHER